±èÁ¤¾Æ ±³¼ö, ´ç´¢º´°ú Áö¹æ°£ Áúȯ ¿¬±¸·Î ÃÖ¿ì¼ö±¸¿¬»ó ¼ö»ó

°í·Á´ë ¾È¾Ïº´¿ø ³»ºÐºñ³»°ú ±èÁ¤¾Æ ±³¼ö, ±¹Á¦Çмú´ëȸ¼­ MASLD¿Í ´ç´¢º´ ¿¬°ü¼º ±Ô¸í ¿¬±¸ ¹ßÇ¥
µî·Ï: 2025.10.02




[¸ÞµðÄÃÅõµ¥ÀÌ=±è¹Ì°æ ±âÀÚ] °í·Á´ëÇб³ ¾È¾Ïº´¿ø ³»ºÐºñ³»°ú ±èÁ¤¾Æ ±³¼ö°¡ Áö³­ 9¿ù 25ÀϺÎÅÍ 27ÀϱîÁö ¼­¿ï ±×·£µå ¿öÄ¿Èú¿¡¼­ ¿­¸° ´ëÇÑ´ç´¢º´ÇÐȸ ±¹Á¦Çмú´ëȸ ¡®2025 KDA Scientific Meeting: 15th International Congress of Diabetes and Metabolism (ICDM2025)¡¯¿¡¼­ ÃÖ¿ì¼ö±¸¿¬»óÀ» ¼ö»óÇß´Ù.



±è ±³¼ö´Â 'Liver-related complications and mortality in type 1 and type 2 diabetes with metabolic dysfunction associated steatotic liver disease'¶ó´Â Á¦¸ñÀÇ ¿¬±¸ ¹ßÇ¥¸¦ ÅëÇØ ¼ö»óÀÇ ¿µ¿¹¸¦ ¾È¾Ò´Ù.



À̹ø ¿¬±¸´Â ´ë»çÀÌ»óÁö¹æ°£Áúȯ(MASLD)À» µ¿¹ÝÇÑ 1Çü ¹× 2Çü ´ç´¢º´ ȯÀÚ¿¡¼­ °£ °ü·Ã ÇÕº´Áõ ¹ß»ý À§ÇèÀÌ Áõ°¡Çϸç, ƯÈ÷ 1Çü ´ç´¢º´ ȯÀÚ¿¡¼­ ÀÌ·¯ÇÑ À§Çèµµ°¡ ´õ¿í ³ô´Ù´Â »ç½ÇÀ» ±Ô¸íÇß´Ù. ÀÌ´Â ÇаèÀÇ Å« ÁÖ¸ñÀ» ¹Þ¾Ò´Ù.



±è ±³¼ö´Â ¿¬±¸ °á°ú ¹ßÇ¥ ÈÄ, "À̹ø ¿¬±¸´Â Á¦1Çü ´ç´¢º´ ȯÀÚ¿¡¼­ ´ë»çÀÌ»óÁö¹æ°£ÁúȯÀÇ ÀÓ»óÀû À§Ç輺À» ±Ô¸íÇß´Ù´Â Á¡¿¡¼­ Å« Àǹ̸¦ °®´Â´Ù"°í ¹àÇû´Ù. ÀÌ¾î ±×´Â "ÇâÈÄ ´ç´¢º´ ȯÀÚ¸¦ ´ë»óÀ¸·Î MASLD¿¡ ´ëÇÑ Àû±ØÀûÀÎ ¼±º°°Ë»ç¿Í ÇÔ²² Ç÷´ç, ´ë»ç ÁöÇ¥, ºñ¸¸¿¡ ´ëÇÑ Á¶±â °ü¸®°¡ ÇÊ¿äÇÏ´Ù"°í °­Á¶Çß´Ù.

±è¹Ì°æ
sallykim0113@mdtoday.co.kr

* º» ±â»çÀÇ ³»¿ëÀº ¸ÞµðÄÃÅõµ¥ÀÌ ¾ð·Ð»ç¿¡¼­ Á¦°øÇÑ ±â»çÀ̸ç ÇコÁ¶¼±ÀÇ ÆíÁý¹æÇâ°ú ÀÏÄ¡ÇÏÁö ¾ÊÀ» ¼öµµ ÀÖ½À´Ï´Ù.(°ü·Ã ¹®ÀÇ´Â ÇØ´ç ¾ð·Ð»ç¿¡ ¿¬¶ôºÎʵ右´Ï´Ù)